Zynex INC 10-Q quarterly reports

Zynex, Inc. reports significant net losses and revenue declines, raising substantial doubt about its ability to continue as a going concern, while grappling with a Tricare payment suspension, multiple lawsuits, and an SEC investigation.

Zynex, Inc. disclosed significant net losses and a substantial revenue decline for the second quarter and first half of 2025, primarily due to a temporary payment suspension from Tricare and reduced device orders, while also revealing an SEC investigation and expressing substantial doubt about its ability to continue as a going concern.

Zynex, Inc. reported a significant 43% drop in net revenue and a net loss of $10.4 million for Q1 2025, primarily driven by a temporary payment suspension from TriCare and a class action lawsuit alleging securities fraud.

Zynex's Q1 2025 revenue decreased by 43% year-over-year due to a temporary payment suspension from TriCare and a decline in device orders.

Zynex's Q3 2024 results show a slight increase in revenue but a decrease in net income compared to the same period last year.

Zynex, Inc. announced an 11% increase in revenue for both the three and six months ended June 30, 2024, driven by increased device orders, though net income decreased compared to the same periods in 2023.

Zynex, Inc. announced a 10% increase in net revenue for the first quarter of 2024, driven by a significant 23% rise in device orders compared to the same period last year.